BNOEF   $0.042  -27.27% Market Closed

Bionomics Ltd
Last Events:

2023-03-29 Trend pattern changed from нисходящий клин to расходящийся клин с наклоном вниз.

2023-03-29 Signal in Stochastic changed from bearish reversal to bearish. The stochastic indicator is in the lower part of the neutral territory and it falls. These factors indicate that negative dynamics persists. Last signal: down-crossing the middle level.

2023-03-29 Signal in RSI changed from bearish to bearish weakening. RSI indicator is in the lower part of the neutral territory and it heading north. These factors indicate that the upside trend is forming Last signal: exit from the overbought zone.

2023-03-29 Signal in EMA20 changed from bearish reversal to bullish reversal. The price is trying to cross up the moving average line If the intersection will be successful, then an upside trend can be formed.

2023-03-29 Trend Power changed from slow to medium strength.

2023-03-29 Trend pattern changed from расходящийся клин с наклоном вниз to нисходящий клин.

2023-03-29 Signal in Stochastic changed from bearish to bearish reversal. The stochastic indicator is in the upper part of the neutral territory and left the overbought territory. These factors indicate that perhaps the upside trend is coming to an end price will probably head south Last signal: main and signal line crossing.

2023-03-29 Signal in RSI changed from bearish weakening to bearish. RSI indicator is in the lower part of the neutral territory and it heading south. These factors indicate that negative dynamics is recovering. Last signal: exit from the overbought zone.


Current temperature: 0.00
ST: 0, Cor:

Analyst Recommendations:
Number of estimates 2
Target Price Mean 8.06
Mean unverified/preliminary 8.06 / 8.06
Target Price Low / High 0.62 / 15.50
Median / STD DEV 8.06 / 15.61
Tech Forecasts:
More signals
  < 1M 1-3M > 3M
total Sell Sell Sell
rsi Buy - Sell
macd Sell Sell -
stoch Sell Sell -
ma20 Sell - -
ma50 Sell - -
ma100 Sell - -
Candlestick PatternMay 11, 2022 Doji - is formed when the open and the close are the same or very close. The body of candle is small. The length of the shadows are not important. The appearance of a Doji should alert the investor of major indecision.
ISIN AU000000BNO5
ceo Dr. Spyridon Papapetropoulos M.D., Ph.D.
Website https://www.bionomics.com.au
Bionomics Limited, a clinical stage biopharmaceutical company, discovers and develops novel drug candidates for the treatment of central nervous system disorders and cancers. The company's lead drug candidate includes BNC210, a negative allosteric modulator of the a7 nicotinic acetylcholine receptor, which is in phase 2 clinical trial for the treatment of social anxiety disorder and phase 2b to treat post-traumatic stress disorder. It also develops BNC101, a monoclonal antibody that has completed phase 1 clinical trial that targets cancer stem cells; and BNC105, which is in phase 2 clinical trial for the treatment of refractory colorectal cancer and phase 1 clinical trial for the treatment of patients with relapsed/refractory chronic lymphocytic leukemia. The company has a collaboration with Merck & Co., Inc. to identify novel a7 Nicotinic Acetylcholine Receptor PAMs suitable for the treatment of cognitive disorder. Bionomics Limited was incorporated in 1996 and is based in Eastwood, Australia.